Bipolar Disorder Market is estimated to be US$ 6.7 billion by 2030 with a CAGR of 2.3% during the forecast period

Bipolar Disorder Market accounted for US$ 5.3 billion in 2020 and is estimated to be US$ 6.7 billion by 2030 and is anticipated to register a CAGR of 2.3%. Bipolar disorder known as manic depression is a mental illness that brings low moods and severe high moods, thinking, changes in sleep and have periods in which they feel overly happy and energized and other side feel very sad, hopeless and sluggish. Bipolar disorder can cause severe disruption to a person’s life which can be treated with appropriate treatment and support.

The report " Global Bipolar Disorder Market, By Disorder (Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder), By Drug Class (Mood Stabilizer, Anticonvulsant, Antipsychotic Drugs, Antidepressant Drugs, and Antianxiety Drugs), By Mechanism of Action (Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, Beta Blockers, and Benzodiazepines), By Region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa) – Trends, Analysis and Forecast till 2030”

Key Highlights:

  • Sept. 18, 2015, new antipsychotic drug (Cariprazine) to treat schizophrenia and bipolar disorder in adults has been approved by the U.S. Food and Drug Administration.

Analyst View:

Increasing prevalence of bipolar disorder drives the market. Government support for spreading awareness and technological advancements that facilitate accurate detection of patient’s mood & mental state drives the market. Antipsychotic drug dominated the market as these drugs overcome the limitations faced by traditional antidepressants as they stabilize the mood.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Bipolar Disorder Market, By Disorder (Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder), By Drug Class (Mood Stabilizer, Anticonvulsant, Antipsychotic Drugs, Antidepressant Drugs, and Antianxiety Drugs), By Mechanism of Action (Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, Beta Blockers, and Benzodiazepines), By Region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa) – Trends, Analysis and Forecast till 2030”

Before purchasing this report, request a sample or make an inquiry by clicking the following link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/1016

Key Market Insights from the report:

The Global Bipolar Disorder Market accounted for US$ 5.3 billion in 2020 and is estimated to be US$ 6.7 billion by 2030 and is anticipated to register a CAGR of 2.3%. The Global Bipolar Disorder Market is segmented based on the disorder, drug class, mechanism of action, and region.

  • By Disorder, the Global Bipolar Disorder Market is segmented into Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder.
  • By Drug Class, the market is segmented Mood Stabilizer, Anticonvulsant, Antipsychotic Drugs, Antidepressant Drugs, and Antianxiety Drugs.
  • By Mechanism of Action, the Global Bipolar Disorder Market is segmented into Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, Beta Blockers, and Benzodiazepines
  • By region, the Global Bipolar Disorder Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. 

Competitive Landscape:

The market key players in the global bipolar disorder market are AstraZeneca limited., Pfizer Inc., Glaxo SmithKline (GSK) Pvt Lt., Eli Lilly Inc., Janssen Pharmaceuticals, Novartis AG pharmaceutical limited, Allergan Plc., Otsuka Holdings Co. Ltd., and AbbVie Inc.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

Other Related Reports:-





Comments

Post a Comment

Popular posts from this blog

Monkeypox Disease Diagnostics Market - The abrupt global expansion of the monkeypox virus has increased the demand for monkeypox diagnostics.

Image
  The virus that causes smallpox and the Monkeypox both belong to the same family of viruses. Two outbreaks of a disease resembling the pox in groups of monkeys used for study led to the discovery of monkeypox in 1958. However, it has been observed in various parts of the world except Africa, where it is primarily found. It results in symptoms that resemble the flu, such as fever, chills, and a rash that might take weeks to go away. Even though instances of monkeypox are uncommon, they are growing in Africa and other areas where they have never before occurred. The fact that monkeypox is a rare disease may lead a healthcare provider to first rule out other rash infections, such measles or chickenpox. A tissue sample from an open sore is the first step in the medical professional's diagnosis of monkeypox (lesion). After that, send to a lab for PCR (Polymerase Chain Reaction). Additionally, blood is drawn to test for antibodies or the monkeypox virus. Currently, there is no licens
Read more

Humanized Liver Mice Model Market is estimated to be US$ 133.72 billion by 2030 with a CAGR of 5.30% during the forecast period

Image
Humanized Liver Mice Model Market   accounted for US$ 78.64 million in 2020 and is estimated to be US$ 133.72 million by 2030 and is anticipated to register a CAGR of 5.30%.  A lot of studies are underway to create novel humanized liver mouse models. Initially, liver mice models were created by implanting human liver cells or hepatic cancer cells into basic immune-deficient mice. The results, however, were inconsistent and unreliable. As a result, immune-deficient mice were developed, which spontaneously destroy the mice liver, allowing human liver cells to proliferate and replace it, resulting in stable humanized liver mice models. For example, a number of research projects are looking into using PPARalfa and AFC8-based mice models to develop humanized liver mice models. The report "Global Humanized Liver Mice Model Market, By Model (uPA-SCID, FRG KO Mice, TK-NOG Mice  and Other Models) By Application (Pharmacokinetics Studies, In-vivo Liver Toxicity Testing, Drug Metabolism Stud
Read more